- Home
- OMI vs TYRA Comparison
OMI vs TYRA Comparison
Compare OMI & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMI
- TYRA
- Stock Information
- Founded
- OMI 1882
- TYRA 2018
- Country
- OMI United States
- TYRA United States
- Employees
- OMI N/A
- TYRA N/A
- Industry
- OMI Medical Specialities
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- OMI Health Care
- TYRA Health Care
- Exchange
- OMI Nasdaq
- TYRA Nasdaq
- Market Cap
- OMI 545.4M
- TYRA 576.6M
- IPO Year
- OMI N/A
- TYRA 2021
- Fundamental
- Price
- OMI $9.46
- TYRA $9.67
- Analyst Decision
- OMI Hold
- TYRA Strong Buy
- Analyst Count
- OMI 6
- TYRA 7
- Target Price
- OMI $12.67
- TYRA $30.86
- AVG Volume (30 Days)
- OMI 1.5M
- TYRA 419.0K
- Earning Date
- OMI 08-01-2025
- TYRA 08-06-2025
- Dividend Yield
- OMI N/A
- TYRA N/A
- EPS Growth
- OMI N/A
- TYRA N/A
- EPS
- OMI N/A
- TYRA N/A
- Revenue
- OMI $10,720,251,000.00
- TYRA N/A
- Revenue This Year
- OMI $3.66
- TYRA N/A
- Revenue Next Year
- OMI $2.52
- TYRA N/A
- P/E Ratio
- OMI N/A
- TYRA N/A
- Revenue Growth
- OMI 2.84
- TYRA N/A
- 52 Week Low
- OMI $6.07
- TYRA $6.42
- 52 Week High
- OMI $16.98
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- OMI 68.48
- TYRA 46.24
- Support Level
- OMI $7.03
- TYRA $9.03
- Resistance Level
- OMI $9.14
- TYRA $9.96
- Average True Range (ATR)
- OMI 0.42
- TYRA 0.65
- MACD
- OMI 0.16
- TYRA -0.06
- Stochastic Oscillator
- OMI 92.89
- TYRA 23.65
About OMI Owens & Minor Inc.
Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.